CAL-101 for SLL ~ Untreated Patients

[Guest guest]

This is a Phase 1/2, open-label, single-arm, efficacy, safety and

pharmacodynamic study of CAL-101 in patients with previously untreated:

Indolent Non-Hodgkin Lymphoma

Follicular Lymphoma

Small Lymphocytic Lymphoma

Marginal Zone B-Cell Lymphoma

Eligible patients will initaite oral therapy with CAL-101 at a starting dose of

150 mg twice per day. Treatment with CAL-101 can continue in compliant patients

for up to twelve 28-day cycles of CAL-101.

Patients who appear to be benefiting from treatment at the completion of 12

cycles of treamtent with CAL-101 may be eligible for participation in a

long-term safety extension study of CAL-101.

Principal Investigator: Ron Levy, MD Stanford University

More: http://clinicaltrials.gov/ct2/show/NCT01306643?term=CLL & recr=Open & rcv_d=14